Balloon Catheter CDMO Service Provider Evaluation
Start with the capability-fit tool, then use the evidence tables to pressure-test extrusion, balloon forming, folding, bonding, coating, and validation transfer claims.
Capability Fit Matrix
Use this tool to identify the manufacturing evidence a balloon catheter CDMO service provider should produce before tooling, validation planning, or supplier shortlisting.
What the Tool Output Should Decide
The page goal is narrow: help a sourcing or R&D team decide whether a balloon catheter CDMO is credible for the next diligence step. It is not a substitute for design verification, regulatory classification, or legal review.
Use the tool first to narrow the CDMO question
Evidence: Application, material, and primary engineering challenge change the evidence you should request from a supplier.
Decision use: A PTCA low-profile program and a peripheral PTA high-pressure program should not receive the same vendor scorecard.
Treat ISO 10555-4 as a floor, not a finished sourcing brief
Evidence: ISO 10555-4:2023 addresses sterile, single-use balloon dilatation catheters; FDA also recognizes the third edition for relevant devices.
Decision use: Supplier audits still need product-specific RBP, compliance, dimensional, simulated-use, packaging, and labeling evidence.
Ask for process evidence before accepting speed claims
Evidence: FDA QMSR expectations make supplier records and quality-system controls part of the manufacturability decision, not back-office paperwork.
Decision use: Fast prototype quotes are weak unless they identify which parameters carry into IQ/OQ/PQ and commercial transfer.
Traceable Sources Used for This Review
Medical device standards and FDA guidance can change. These links were checked on July 18, 2026; final evidence requirements still depend on intended use, jurisdiction, risk classification, and product-specific claims.
| Source | Date signal | How it informs sourcing |
|---|---|---|
| ISO 10555-4:2023 | Published November 2023; checked July 18, 2026 | Baseline reference for sterile, single-use balloon dilatation catheter requirements and balloon-material selection context. |
| FDA recognized consensus standard 6-498 | Recognition entry May 29, 2024; page updated May 25, 2026 | Confirms FDA recognition of ISO 10555-4 third edition and links it to relevant catheter product codes and guidance. |
| FDA PTA and specialty catheter 510(k) guidance | Issued April 2023; content current April 14, 2023 | Frames non-clinical testing, animal or clinical evidence when warranted, and labeling expectations for PTA balloon and specialty catheters. |
| FDA QMSR FAQ | Effective and content current February 2, 2026 | Explains the U.S. transition from QS regulation framing to QMSR alignment with ISO 13485:2016 expectations. |
Core Capabilities to Evaluate
Avoid generic capability decks. A credible supplier should connect each manufacturing step to measurement records, acceptance criteria, failure-mode learning, and transfer ownership.
| Capability | Ask the CDMO | Proof to request | Warning sign |
|---|---|---|---|
| Extrusion and tubing control | Which lumen, wall, outer-diameter, concentricity, drying, and in-line measurement controls are recorded by lot? | Representative process capability data, calibration records, material traceability, and nonconformance examples. | The supplier quotes tight dimensions but cannot show how measurements are taken before balloon forming. |
| Balloon forming and cone control | How are stretch, temperature, pressure, mold, neck, and cone parameters locked across the full diameter and length matrix? | Development DOE summary, forming recipe history, RBP and compliance curves, and worst-case sample rationale. | Only best-case burst data is shared, with no rationale for smallest and largest sizes. |
| Pleating, folding, and rewrap | Can the CDMO measure profile after folding, coating, sterilization simulation, and inflation/deflation cycles? | Profile measurement method, fold inspection standard, heat-set controls, and simulated-use withdrawal evidence. | The vendor treats folding as a manual finishing step without recipe control. |
| Bonding and shaft transition | Which laser, thermal reflow, adhesive, or weld controls protect bond strength without creating a stiff transition? | Bond strength data, microscopy, leak tests, kink evidence, and failure-mode trending by shaft family. | Balloon and shaft teams operate separately and cannot explain interface ownership. |
| Coating or drug-surface integration | Is the project hydrophilic, drug-coated, or otherwise a combination-product candidate, and who owns particulate and coating integrity evidence? | Surface activation records, coating inspection data, particulate plan, and regulatory pathway assumptions. | The quote assumes a standard catheter pathway before drug or coating status is resolved. |
Keep Feasibility Evidence Connected to IQ/OQ/PQ
Validation timelines are supplier- and product-specific. Instead of relying on a generic 4-8 week claim, require the CDMO to show which prototype assumptions become controlled process inputs and which still need characterization.
Discovery brief
Intended use, anatomical path, size matrix, pressure target, balloon material assumption, and coating status.
Feasibility lots
Prototype data that ties failures to extrusion, forming, folding, coating, or bonding variables.
Design freeze
Locked drawings, acceptance criteria, worst-case rationale, and supplier-owned process assumptions.
Validation transfer
IQ/OQ/PQ plan, measurement-system readiness, process monitoring, and commercial lot-release evidence.
Turn the screen into a supplier evidence request
Send drawings, size matrix, pressure target, material assumption, and evidence gaps for a focused feasibility review.
CDMO Sourcing Scenarios: Material vs. Application
The dimensions below are not universal pass/fail targets. Use them to ask for product-specific drawings, test methods, and acceptance criteria tied to your balloon size matrix.
| Material | Best sourcing fit | Audit focus | Caveat |
|---|---|---|---|
| PET | Non-compliant or high-pressure balloon programs | Forming pressure window, pinhole detection, cone repeatability, fold memory, and RBP statistics. | Low elongation can make folding and profile management harder, especially at small diameters. |
| Nylon | Semi-compliant coronary or peripheral designs | Moisture handling, drying records, compliance curve stability, tubing variability, and bond compatibility. | Material conditioning can change process behavior, so lot controls matter as much as nominal resin choice. |
| Pebax | Flexible, low-profile, or neurovascular designs | Thermal forming window, shaft bonding, coating interaction, profile after conditioning, and small-lot repeatability. | Thermal and bonding windows can narrow quickly on thin-wall or highly flexible assemblies. |
| Polyurethane | Compliant occlusion, sizing, or sealing balloons | Elastic recovery, leak testing, tack handling, dimensional recovery, and packaging contact risk. | Useful where expansion is intentional, but less appropriate when diameter control must be very tight. |
Key Risks and Trade-offs in CDMO Selection
Speed hides validation debt
Risk: A supplier can build attractive pilot samples with manual corrections that cannot be repeated during validation.
Control: Ask which prototype parameters become controlled process inputs and which are still exploratory.
Tooling terms lock in the wrong partner
Risk: Low upfront mold cost can come with restricted transfer rights, limited parameter disclosure, or unclear ownership of custom fixtures.
Control: Define mold, fixture, recipe, inspection-method, and transfer-data ownership before purchase orders are issued.
Regulatory pathway is assumed too early
Risk: Drug-coated, scoring, cutting, neurovascular, or structural-heart applications can change evidence needs materially.
Control: Separate base-balloon manufacturability from final regulatory strategy and document assumptions by jurisdiction.
Frequently Asked Questions
What should a balloon catheter CDMO service provider prove first?
Ask first for evidence that matches the hardest failure mode in your design: RBP and compliance for pressure risk, folded profile and rewrap for deliverability risk, particulate and coating integrity for surface risk, or pilot-to-validation transfer controls for speed risk.
Can one CDMO handle extrusion, forming, folding, and assembly?
Some can, but the useful question is whether one quality system controls the handoff. If extrusion, balloon forming, shaft bonding, and folding are split across teams or sites, require a documented interface-control plan and lot traceability.
Does ISO 10555-4 approval mean the supplier is qualified?
No. ISO 10555-4 is a relevant standard for balloon dilatation catheter requirements, but supplier qualification still needs product-specific design verification, process validation, risk management, and quality-system evidence.
How should we compare fast prototype quotes?
Compare the quote by retained learning, not only lead time. A useful quote states what drawings, recipes, fixtures, test methods, lot records, and failure analyses will survive into design freeze and validation transfer.
When is material selection still too open for tooling?
If pressure target, compliance behavior, profile target, coating status, or anatomical route is unsettled, keep material as a discovery variable and avoid locking custom tooling until the trade-off is documented.
What evidence matters for PTA or specialty catheter submissions?
FDA guidance for PTA and specialty catheter 510(k) submissions frames expected non-clinical testing, animal or clinical evidence when warranted, and labeling. The exact package depends on product type and whether the device is a combination product.
Continue the Diligence Path
Inquiry Email
Include OD/ID, shaft stack, prototype quantity, and delivery location.